InsiderDB

Lobbying disclosures · Lobbying report

PFE: third_quarter 2026 lobbying report

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage. Medicare/Medicaid Issues.

Follow PFE
Became public
Oct 19, 2026, 11:44 AM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 8:08 AM EST

Why this is connected

Exact legal-name match: PFIZER INC (https://www.sec.gov/Archives/edgar/data/78003/).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/366f4f34-546a-4998-a758-6a16d8a8e32a/","filing_uuid":"366f4f34-546a-4998-a758-6a16d8a8e32a","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/366f4f34-546a-4998-a758-6a16d8a8e32a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-19T11:44:13-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":57633,"url":"https://lda.gov/api/v1/clients/57633/","client_id":57633,"name":"PFIZER INC.","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-07-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare/Medicaid Issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in PFE

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.